Literature DB >> 9703615

Chemoprophylaxis of Theileria annulata and Theileria parva infections of calves with buparvaquone.

G M Wilkie1, C G Brown, B E Kirvar, M Thomas, S M Williamson, L J Bell-Sakyi, O Sparagano.   

Abstract

A clinical trial testing the prophylactic effect of a 5 mg kg-1 dose of buparvaquone on either Theileria annulata or Theileria parva experimental infections of calves demonstrated its efficacy for periods of at least seven days. The drug given 1 h or seven days before 50% lethal T. annulata sporozoite infection protected all eight calves, but prophylaxis was insufficient after 14 days to protect two out of four calves from severe reaction. When immunity was challenged by a lethal second parasite dose a month after the first, all these calves were immune. In the T. parva trial, calves given drug 1 h or seven days before a 25% lethal infection underwent minimal reaction, but some were over-protected and were susceptible to a similar challenge sporozoite dose. Although drug levels remaining 14 days after prophylaxis protected these calves from the mild challenge, some parameters measured were within the range of the 'no drug' control group. These results indicated the effectiveness of a single 5 mg kg-1 dose of buparvaquone for more than seven days but also the potential risk of its use in the infection and treatment method of immunisation. It is suggested that there may be circumstances where simple field prophylactic treatment with buparvaquone may be beneficial.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9703615     DOI: 10.1016/s0304-4017(98)00126-5

Source DB:  PubMed          Journal:  Vet Parasitol        ISSN: 0304-4017            Impact factor:   2.738


  1 in total

1.  Buparvaquone is active against Neospora caninum in vitro and in experimentally infected mice.

Authors:  Joachim Müller; Adriana Aguado-Martinez; Vera Manser; Vreni Balmer; Pablo Winzer; Dominic Ritler; Isabel Hostettler; David Arranz-Solís; Luis Ortega-Mora; Andrew Hemphill
Journal:  Int J Parasitol Drugs Drug Resist       Date:  2015-02-13       Impact factor: 4.077

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.